Joseph Presti, Jr.

Administrative Appointments

• Associate Chair, Stanford University School of Medicine - Urology (2001 - present)
• Director, Urologic Oncology Program, Division of Urologic Oncology (2000 - present)

Honors and Awards

• Thomas A. Stamey Research Professor in Urology, Stanford University (April 2008)

Professional Education

Graduate & Fellowship Program Affiliations

• Urology

Current Research Interests

refine detection strategies for prostate cancer, identify prognostic indicators for prostate cancer patients

Clinical Trials

• A Comprehensive Study to Isolate Tumor-initiating Cells from Human Epithelial Malignancies Recruiting
• Microarray Analysis of Gene Expression in Prostate Tissues Recruiting
• Prostate Active Surveillance Study (PASS) Recruiting
• Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance Withdrawn
• Long-Term Follow-Up Study of Patients Who Were Diagnosed With Prostate Cancer While Undergoing Treatment on a Prostate Cancer Prevention Trial Completed

Publications

• Dietary calcium and risk for prostate cancer: a case-control study among US veterans. Williams CD, Whitley BM, Hoyo C, Grant DJ, Schwartz GG, Presti JC, Iraggi JD, Newman KA, Gerber L, Taylor LA, McKeever MG, Freedland SJ. Prev Chronic Dis. 2012: 9 E39
• Does Salvage Radiation Therapy Change the Biology of Recurrent Prostate Cancer Based on PSA Doubling Times? Results from the SEARCH Database. Muller RL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Urology. 2012
• Effect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen. Woodard G, Ahmed S, Podelski V, Hernandez-Boussard T, Presti J, Morton JM. Br J Surg. 2012
• Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Chu DI, Moreira DM, Gerber L, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Cancer. 2012
• Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. King CR, Brooks JD, Gill H, Presti JC. Int J Radiat Oncol Biol Phys. 2012; 82 (2): 877-82